Challenges of Delivering Diabetes Care During the Covid 19 Pandemic

Susan E Jones

doi:10.70302/jpsim.v2i3.2143

Editorial

Challenges of Delivering Diabetes Care During the Covid 19 Pandemic

Susan E Jones

North Tees University Hospital, Stockton on Tees, UK. Newcastle University Medical School

✉ Correspondence: Susan E Jones Email: sue.jones20@nhs.net

DOI https://doi.org/10.70302/jpsim.v2i3.2143

Volume: 2, Issue 3 Pages: 186–187 Published: 20 Sep 2021

Received: 26 May 2021 Accepted: 13 Aug 2021 Published Online: 20 Sep 2021

Abstract

How to Cite This Article

Jones SE. Challenges of Delivering Diabetes Care During the Covid 19 Pandemic. J Pak Soc Intern Med. 2021;2(3):186–187. doi:10.70302/jpsim.v2i3.2143

⭳ Download XML (JATS) ⭳ Download PDF

Download Citation: ⭳ RIS (Endnote / Zotero / Mendeley) ⭳ BibTeX (.bib)

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

NHS Attend Anywhere. [ Cited July 2021] Available from: [https://england.nhs.attendanywhere.com/resourcecentre/Content/Home.htm]
Iyengar K, Jain VK, Vaishya R. Pitfalls in telemedicine consultations in the era of COVID 19 and how to avoid them. Diabetes & Metabolic Syndrome: Clin Res Rev. 2020 ;14(5):797-9.
Marsalek K, Pevtrignet S. Understanding the needs of the most clinically vulnerable to COVID-19. Unanswered questions about the shielded population. The Health Foundation. [Updated 2020, cited 2021] Available from: [https://www.health.org.uk/news-and-comment/charts-and-infographics/understanding-the-needs-and-experiences-of-those-most-clinic]
Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, et al. New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic. Diabetic Medicine, 2020;37(7): 1210-13.
The RECOVERY Trial Group. [Udated 2020, cited 2021] Available from: [https://www.recoverytrial.net/]
The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. NEJM 2020;doi.10.1056/NEJMoa2021436 doi:10.1056/NEJMoa2021436
Rubino F, Amiel S, Zimmet P, Alberti G, Bornstein S, Eckel R et,al. New Onset Diabetes in COVID-19. NEJM 2020;383(8):789 -90
Taylor S, Blau J, Rother K. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endo Metab. 2015; 100 (8):2849-52
Kosiborod M, Esterline R, Futado R, Ocarsson J, Gasparyan S, Koch G et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diab Endocrinol. 2021;9(9):586 -94.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

🔗 Related Articles

Editorial Confronting the HIV/AIDS Epidemic in Khyber Pakhtunkhwa—A Critical Public Health Challenge Salma Zeb Editorial One Health A New Paradigm for Global Health in the 21st Century Prof. Aziz-ur-Rehman Editorial HYPOSKILLIA: The Quiet Atrophy of Clinical Judgement A Call to Restore Bedside Medicine Arif M. Siddiqui Editorial Air Pollution and Its Impact on Human Health Asif Hussain Editorial Towards Elimination of Chronic Hepatitis B: How Close are We? Zaigham Abbas

[1] NHS Attend Anywhere. [ Cited July 2021] Available from: [https://england.nhs.attendanywhere.com/resourcecentre/Content/Home.htm]

[2] Iyengar K, Jain VK, Vaishya R. Pitfalls in telemedicine consultations in the era of COVID 19 and how to avoid them. Diabetes & Metabolic Syndrome: Clin Res Rev. 2020 ;14(5):797-9.

[3] Marsalek K, Pevtrignet S. Understanding the needs of the most clinically vulnerable to COVID-19. Unanswered questions about the shielded population. The Health Foundation. [Updated 2020, cited 2021] Available from: [https://www.health.org.uk/news-and-comment/charts-and-infographics/understanding-the-needs-and-experiences-of-those-most-clinic]

[4] Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, et al. New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic. Diabetic Medicine, 2020;37(7): 1210-13.

[5] The RECOVERY Trial Group. [Udated 2020, cited 2021] Available from: [https://www.recoverytrial.net/]

[6] The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. NEJM 2020;doi.10.1056/NEJMoa2021436 doi:10.1056/NEJMoa2021436

[7] Rubino F, Amiel S, Zimmet P, Alberti G, Bornstein S, Eckel R et,al. New Onset Diabetes in COVID-19. NEJM 2020;383(8):789 -90

[8] Taylor S, Blau J, Rother K. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endo Metab. 2015; 100 (8):2849-52

[9] Kosiborod M, Esterline R, Futado R, Ocarsson J, Gasparyan S, Koch G et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diab Endocrinol. 2021;9(9):586 -94.